SG11201606595RA - Treatment of h. pylori infections using mtan inhibitors - Google Patents

Treatment of h. pylori infections using mtan inhibitors

Info

Publication number
SG11201606595RA
SG11201606595RA SG11201606595RA SG11201606595RA SG11201606595RA SG 11201606595R A SG11201606595R A SG 11201606595RA SG 11201606595R A SG11201606595R A SG 11201606595RA SG 11201606595R A SG11201606595R A SG 11201606595RA SG 11201606595R A SG11201606595R A SG 11201606595RA
Authority
SG
Singapore
Prior art keywords
treatment
pylori infections
mtan inhibitors
mtan
inhibitors
Prior art date
Application number
SG11201606595RA
Inventor
Vern L Schramm
Keith Clinch
Shivali Ashwin Gulab
Original Assignee
Einstein Coll Med
Victoria Link Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Einstein Coll Med, Victoria Link Ltd filed Critical Einstein Coll Med
Publication of SG11201606595RA publication Critical patent/SG11201606595RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Engineering & Computer Science (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG11201606595RA 2014-02-12 2015-02-06 Treatment of h. pylori infections using mtan inhibitors SG11201606595RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461938755P 2014-02-12 2014-02-12
PCT/US2015/014778 WO2015123101A1 (en) 2014-02-12 2015-02-06 Treatment of h. pylori infections using mtan inhibitors

Publications (1)

Publication Number Publication Date
SG11201606595RA true SG11201606595RA (en) 2016-09-29

Family

ID=53800544

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201606595RA SG11201606595RA (en) 2014-02-12 2015-02-06 Treatment of h. pylori infections using mtan inhibitors
SG10201806381VA SG10201806381VA (en) 2014-02-12 2015-02-06 Treatment of h. pylori infections using mtan inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201806381VA SG10201806381VA (en) 2014-02-12 2015-02-06 Treatment of h. pylori infections using mtan inhibitors

Country Status (12)

Country Link
US (2) US10118928B2 (en)
EP (1) EP3104707B1 (en)
JP (1) JP6512613B2 (en)
AU (1) AU2015217416B2 (en)
BR (1) BR112016019469B1 (en)
CA (1) CA2974916C (en)
HK (1) HK1232071A1 (en)
IL (1) IL247218B (en)
NZ (1) NZ724103A (en)
RU (1) RU2663803C2 (en)
SG (2) SG11201606595RA (en)
WO (1) WO2015123101A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014025842A1 (en) 2012-08-07 2014-02-13 Albert Einstein College Of Medicine Of Yeshiva University Treatment of helicobacter pylori infections
CN108794628A (en) * 2018-05-28 2018-11-13 广东工业大学 A kind of Yolk antibody preparation method and application of anti-helicobacter pylori

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985848A (en) 1997-10-14 1999-11-16 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of nucleoside metabolism
US7098334B2 (en) 2002-03-25 2006-08-29 Industrial Research Limited 4-amino-5H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases
PL374191A1 (en) * 2002-06-13 2005-10-03 Vertex Pharmaceuticals Incorporated 2-ureido-6-heteroaryl-3h-benzoimidazole-4-carboxylic acid derivatives and related compounds as gyrase and/or topoisomerase iv inhibitors for the treatment of bacterial infections
EP1539783B1 (en) 2002-08-21 2011-04-13 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of nucleoside phosphorylases and nucleosidases
NZ533360A (en) 2004-06-04 2007-02-23 Ind Res Ltd Improved method for preparing 3-hydroxy-4-hydroxymethyl-pyrrolidine compounds
AU2006275725A1 (en) 2005-07-27 2007-02-08 Albert Einstein College Of Medicine Of Yeshiva University Transition state structure of 5'-methylthioadenosine/s-adenosylhomocysteine nucleosidases
PL2057165T3 (en) 2006-09-07 2011-08-31 Victoria Link Ltd Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases
WO2008030118A1 (en) * 2006-09-07 2008-03-13 Industrial Research Limited Acyclic amine inhibitors of 5'-methylthioadenosine phosphorylase and nucleosidase
CN101600711A (en) 2006-12-22 2009-12-09 工业研究有限公司 The azetidine analogues of nucleosidase and phosphorglase inhibitor
WO2008115531A1 (en) 2007-03-21 2008-09-25 Novacea, Inc. Prevention and treatment of infectious conditions with active vitamin d compounds or mimics thereof
WO2010033236A2 (en) * 2008-09-22 2010-03-25 Albert Einstein College Of Medicine Of Yeshiva University Methods and compositions for treating bacterial infections by inhibiting quorum sensing
EP2454263B1 (en) 2009-07-17 2018-06-13 Albert Einstein College of Medicine, Inc. 3-hydroxypyrrolidine inhibitors of 5'-methylthioadenosine phosphorylase and nucleosidase
WO2012074912A1 (en) * 2010-11-29 2012-06-07 Albert Einstein College Of Medicine Of Yeshiva University Methods, assays and compounds for treating bacterial infections by inhibiting methylthioinosine phosphorylase
WO2014025842A1 (en) 2012-08-07 2014-02-13 Albert Einstein College Of Medicine Of Yeshiva University Treatment of helicobacter pylori infections
US9522159B2 (en) 2012-09-11 2016-12-20 Albert Einstein College Of Medicine, Inc. Treatment and prevention of P. aeruginosa infections using coformycin analogs
US9994574B2 (en) 2012-11-12 2018-06-12 Victoria Link Limited Salt and polymorphic forms of (3R,4S)-L-((4-amino-5H-pyrrolo[3,2,-d]pyrimidin-7-yl)methyl)-4(methylthiomethyl)pyrodin-3-ol(MTDIA)

Also Published As

Publication number Publication date
CA2974916C (en) 2022-05-31
WO2015123101A1 (en) 2015-08-20
US20170166571A1 (en) 2017-06-15
US10118928B2 (en) 2018-11-06
BR112016019469A2 (en) 2018-07-24
JP6512613B2 (en) 2019-05-15
IL247218B (en) 2020-06-30
JP2017506238A (en) 2017-03-02
EP3104707A4 (en) 2017-12-13
CA2974916A1 (en) 2015-08-20
RU2663803C2 (en) 2018-08-09
SG10201806381VA (en) 2018-08-30
RU2016136533A3 (en) 2018-06-06
RU2016136533A (en) 2018-03-13
AU2015217416A1 (en) 2016-09-29
HK1232071A1 (en) 2018-01-05
US10294233B2 (en) 2019-05-21
AU2015217416B2 (en) 2018-10-04
BR112016019469B1 (en) 2022-12-06
IL247218A0 (en) 2016-09-29
NZ724103A (en) 2020-07-31
US20190016730A1 (en) 2019-01-17
EP3104707B1 (en) 2020-07-15
EP3104707A1 (en) 2016-12-21

Similar Documents

Publication Publication Date Title
IL252839A0 (en) Treatment of pemphigus
GB201701673D0 (en) Methods of well treatment
SG11201609652RA (en) Treatment of polybacterials infections
SG11201702688UA (en) Methods of treating rsv infections
GB201608885D0 (en) Treatment
GB201522243D0 (en) Treatment
GB201502137D0 (en) Treatment
GB201421845D0 (en) Fluid treatment system
GB201416832D0 (en) Methods of treatment
GB201508841D0 (en) Treatment
HK1232071A1 (en) Treatment of h. pylori infections using mtan inhibitors mtan h.pylori
HUE047940T2 (en) Erythromelalgia treatment
GB201412010D0 (en) Treatment of hypertransaminasemia
GB201411027D0 (en) Treatment
HK1217430A1 (en) Surface treatment agent
GB201512139D0 (en) Methods of treatment
GB201503008D0 (en) Treatment
GB201617107D0 (en) Treatment
GB201612260D0 (en) Treatment
GB201612193D0 (en) Treatment
GB201609683D0 (en) Treatment
GB201518349D0 (en) Treatment
GB201515739D0 (en) Treatment
GB201514008D0 (en) Treatment
GB201413317D0 (en) Atheroscierosis treatment